Protagonist Logo. Click to navigate to a home page

J&J notebook: Highlights from a day of pipeline and strategy discussion

By Max Gelman | December 6, 2023

Johnson & Johnson laid out their pipeline and medtech strategies Tuesday, promising 20 new drugs that can help grow sales 5% to 7% a year through 2030, starting with $57 billion in 2025. R&D chief John Reed, in an earlier interview with Endpoints News, said their three pillars of focus would be oncology, immunology and neuroscience.

CONTINUE READING
Share by: